7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication

After being informed about the study details, all eligible participants (or their legal guardians) will give informed written consent to be involved. After a one week screening, eligible participants will be randomized to Vonoprazan plus Amoxicillin plus Clarithromycin triple therapy for either 14 days (group 1), or 7 days (group 2) at a 1:1 ratio. After the end of therapy, H. Pylori eradication will be evaluated after 4 weeks.

Inclusion criteria

• Participants in the age group (10-18 years), both genders, referred with dyspeptic complaints such as heartburn, dyspepsia, nausea, and epigastric pain who are positive for H. Pylori infection by a standardized diagnostic test.
• Pediatric patients with a clinical, laboratory, and endoscopic diagnosis of H.P.-positive gastritis and the other conditions necessary for H.P. eradication, according to the Maastricht V consensus report .

Exclusion criteria

• allergy to any of the drugs used in the study
• previous attempts to eradicate H.P.
• receipt of antibiotics, PPIs, bismuth, H2 antagonists or probiotics within 4 weeks of the study.
• Children with the diagnosis of any condition that might affect the absorption of drugs such as celiac disease or Crohn's disease.
• hepatic impairment or kidney failure.
• symptoms suggestive of functional disorders.